pentapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-18. Numbers and descriptions here follow the published literature rather than marketing material.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
Vasculogenesis is the process of blood vessel formation, occurring by a de novo production of endothelial cells. It is the first stage of the formation of the vascular network, closely followed by angiogenesis. This is the creation of blood vessels during early development particularly in embryos. Blood vessels start to form from special cells known as endothelial progenitor cells. While this process mostly happens during embryonic development, it can also occur in adults when the body needs to repair damaged blood vessels or grow new ones after an injury occurs. Vasculogenesis is the formation of new blood vessels, in blood islands, which first arise in the mesoderm of the yolk sac at 3 weeks of development, when there are no pre-existing ones. For example, if a monolayer of endothelial cells begins sprouting to form capillaries, angiogenesis is occurring. Vasculogenesis, in contrast, is when endothelial precursor cells (angioblasts) migrate and differentiate in response to local cues (such as growth factors and extracellular matrices) to form new blood vessels. These vascular trees are then pruned and extended through angiogenesis. Vasculogenesis can also arise in the adult organism from circulating endothelial progenitor cells (derivatives of stem cells). These cells are able to contribute, albeit to varying degrees, to neovascularization. Examples of where vasculogenesis can occur in adults are:
== Structure == Bradykinin, sometimes referred to as BK, is a 9–amino acid peptide chain. The amino acid sequence of bradykinin is: Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg (RPPGFSPFR). Its empirical formula is therefore C50H73N15O11.
=== Durability === Mid-term durability from ESG appears promising. A total body weight loss of 17% and excess weight loss of between approximately 60-67% was observed to be sustained at 18–24 months. This was later confirmed in the multicenter, randomized controlled MERIT study, which observed that 68% of subjects who underwent an ESG maintained 25% or more of their excess weight loss at two years. As a novel therapy, ESG presently lacks studies assessing long-term durability, though more data on this component of ESG are anticipated as more ESGs are performed over time. One recent study observed at 5 years from ESG that at least 10% total body weight loss was maintained in 90% of patients and at least 15% total body weight loss was maintained in 61% of patients.
Campbell and Satoshi Ōmura; she received it "for her discoveries concerning a novel therapy against Malaria". 2015: American inventor and clean water advocate Deepika Kurup invented a photocatalytic composite material that removes 100% of faecal coliform bacteria from contaminated water. Deepika won the Discovery Education 3M Young Scientist Challenge award and The US Stockholm Junior Water Prize for her work. 2015: Asha de Vos became the first Sri Lankan person to receive a PhD in marine mammal research, completing her thesis on "Factors influencing blue whale aggregations off southern Sri Lanka" at the University of Western Australia. 2016: American geophysicist Marcia McNutt became the first female president of the American National Academy of Sciences. 2016: French-Algerian particle physicist Yasmine Amhis was awarded the Jacques Herbrand Prize given by the French Academy of Sciences 2018: British astrophysicists Hiranya Peiris and Joanna Dunkley and Italian cosmologist Licia Verde were among 27 scientists awarded the Breakthrough Prize in Fundamental Physics for their contributions to "detailed maps of the early universe that greatly improved our knowledge of the evolution of the cosmos and the fluctuations that seeded the formation of galaxies". 2018: British astrophysicist Jocelyn Bell Burnell received the special Breakthrough Prize in Fundamental Physics for her scientific achievements and "inspiring leadership", worth $3 million.
== Background == Robert Karriem was born Robert Harris on August 3, 1888, to parents Alec and Lulu in Mississippi. On July 3, 1929, he moved to Detroit, Michigan. He had a wife, Bertha. James Smith was born on December 25, 1892, in Atlanta. In 1930, a man named W. D. Fard came to Detroit, ultimately founding a group called the Allah Temple of Islam. Among Fard's practices was to give new, Islamic names to members, replacing their inherited 'slave names'. Harris was given the new surname "Karriem".
Sources: en.wikipedia.org
In some other invertebrates such as earthworms, the circulatory system is not used to transport oxygen and so is much reduced, having no veins or arteries and consisting of two connected tubes. Oxygen travels by diffusion and there are five small muscular vessels that connect these vessels that contract at the front of the animals that can be thought of as "hearts". Squids and other cephalopods have two "gill hearts" also known as branchial hearts, and one "systemic heart". The branchial hearts have two atria and one ventricle each, and pump to the gills, whereas the systemic heart pumps to the body.
Central nervous disorders are not uncommon, but the blood brain barrier (BBB) often blocks access of potential therapeutics to the brain. siRNAs that target and silence efflux proteins on the BBB surface have been shown to create an increase in BBB permeability. siRNA delivered via lipid based nanoparticles is able to cross the BBB completely. A huge difficulty in siRNA delivery is the problem of off-targeting. Since genes are read in both directions, there exists a possibility that even if the intended antisense siRNA strand is read and knocks out the target mRNA, the sense siRNA strand may target another protein involved in another function. Phase I results of the first two therapeutic RNAi trials (indicated for age-related macular degeneration, aka AMD) reported at the end of 2005 that siRNAs are well tolerated and have suitable pharmacokinetic properties. In a phase 1 clinical trial, 41 patients with advanced cancer metastasised to liver were administered RNAi delivered through lipid nanoparticles. The RNAi targeted two genes encoding key proteins in the growth of the cancer cells, vascular endothelial growth factor, (VEGF), and kinesin spindle protein (KSP). The results showed clinical benefits, with the cancer either stabilized after six months, or regression of metastasis in some of the patients. Pharmacodynamic analysis of biopsy samples from the patients revealed the presence of the RNAi constructs in the samples, proving that the molecules reached the intended target.
== Signs and symptoms == Symptoms of bone sarcomas typically include bone pain, especially at night, and swelling around the site of the tumor. Symptoms of soft-tissue sarcomas vary, but they often present as firm, oftentimes painless lumps or nodules. Gastrointestinal stromal tumors (GIST, a subtype of soft-tissue sarcoma) often are asymptomatic, but can be associated with vague complaints of abdominal pain, bleeding into the intestines, a feeling of fullness, or other signs of intestinal obstruction.
== History == In 1987, Dynacare Health Group acquired its first diagnostic laboratory—Quality Medical Laboratories and established Dynacare Laboratories. By 2015, Dynacare was part of the Central Medical Laboratories (CML), established in 1959 in Winnipeg, Manitoba. Dynacare was formed with the formation of an "operational partnership" in 1997 between Ontario's Bio-Science Laboratory and Gamma North Peel Partnership Inc. In 2002, Laboratory Corporation of America (LabCorp) acquired Dynacare Laboratories—one of the Dynacare partners—for US$480-million, while also assuming Dynacare debt worth $205-million. By 2002, Dynacare, just before LabCorp's takeover, had become the largest central clinical laboratory in western Canada, with a revenue in 2001 of $402.4-million and a profit of $11.7-million. By June 2020, DynaLIFE was operating 36 private laboratories in the Edmonton area and northern Alberta and had a contract with the Alberta government that is set to expire in 2022. In June 2020, Alberta Health Services, announced plans to outsource public community laboratory services to private companies. Gamma-Dynacare acquired LifeLabs Quebec. In 2013, DynaLIFE Medical Labs partnered with Dynacare, which operates laboratories in Alberta and across Canada. In 2015, Gamma-Dynacare Medical Laboratories rebranded itself back to Dynacare.
Ram Krishna Nagar State assembly constituency is one of the 126 state legislative assembly constituencies in Assam, India. It is one of the six assembly segments that constitute the Karimganj Lok Sabha constituency. Since 2019, it has been represented by Bijoy Malakar of the Bharatiya Janata Party. Originally established as Ratabari in 1962, the constituency was redrawn during the 2023 delimitation exercise and was renamed to Ram Krishna Nagar. The reconstituted constituency now includes Ramkrishna Nagar town, and many other rural areas of the Sribhumi district.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.